SLC5A2 and type 2 diabetes mellitus: Across a range of studies involving healthy volunteers and patients with T2DM, co-administration of metformin with various SGLT2 inhibitors—including canagliflozin, dapagliflozin, ertugliflozin, ipragliflozin, luseogliflozin—resulted in only modest changes in metformin exposure [74,75,76,77,78,79,80,81,82].